Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis. A comparison of cycling versus swapping strategies

Rheumatoid Arthritis

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Ann Rheum Dis.

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM

doi: 10.1136/annrheumdis-2020-217209.

Rheumatoid Arthritis

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Arthritis Rheumatol.

Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR

doi: 10.1002/art.39944.

Rheumatoid Arthritis

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry

J Rheumatol.

Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL

doi: 10.3899/jrheum.151014

Rheumatoid Arthritis

Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets

Exp Ther Med.

Davis LS, Reimold AM

doi: 10.3892/etm.2017.4265.

Rheumatoid Arthritis

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register

BMC Musculoskelet Disord.

McWilliams DF, Walsh DA

doi: 10.1186/s12891-016-1192-7.

COMMENTED

PsoriasisRheumatoid Arthritis

Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

★ 3 Recommended and commented by PD Dr Luc Biedermann, Faculty Member

doi: 10.1016/S2468-1253(19)30362-0.

Rheumatoid Arthritis

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

RMD Open.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R

doi: 10.1136/rmdopen-2016-000416.

Psoriatic ArthritisRheumatoid Arthritis

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

Ann Rheum Dis

Christensen IE, Lillegraven S, Mielnik P, Bakland G, Loli L, Sexton J, Uhlig T, Kvien TK, Provan SA

doi: 10.1136/annrheumdis-2021-221007

Psoriasis

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

J Am Acad Dermatol.

Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A

doi: 10.1016/

Related content

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry

Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register

Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study